Comparison of Legacy Fatigue Measures With the PROMIS Pediatric Fatigue Short Form

Macpherson, Catherine Fiona; Wang, Jichuan; DeWalt, Darren A.; Stern, Emily; Jacobs, Shana; Hinds, Pamela S.

doi:10.1188/18.onf.106-114

Cited by 12 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional validity detail is found in the results of the GEE model test in which being older (13 to 18 years old) and higher anxiety and depression scores predicted higher fatigue. Similar findings have been found in previously completed PRO studies using disease‐ and age‐specific measures . This replication in findings with PROMIS measures adds support for their validity.…”

Section: Discussionsupporting

confidence: 87%

“…Similar findings have been found in previously completed PRO studies using disease-and agespecific measures. 1,34,37,49,50 This replication in findings with PROMIS measures adds support for their validity. Overall, study findings support the readiness of most of these measures to be embedded in pediatric oncology clinical trials to document more completely the full impact of cancer treatments on children and adolescents.…”

Section: Discussionmentioning

confidence: 58%

“…Historically, disease‐specific measures were thought to have greater sensitivity to change . However, modern test theory enables general instruments such as the PROMIS pediatric measures to have equivalent or superior test characteristics to age‐ and disease‐specific instruments …”

Section: Introductionmentioning

confidence: 99%

“…31 However, modern test theory enables general instruments such as the PROMIS pediatric measures to have equivalent or superior test characteristics to ageand disease-specific instruments. [32][33][34] In the United States, 12 400 children are diagnosed with cancer annually, 1 and more than 90% receive chemotherapy as a standard part of their treatment. Chemotherapy negatively affects scores on PROs, including fatigue, nausea, vomiting, emotional distress, altered sleep quality, and poor social and physical function.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

Hinds

Wang

Cheng

et al. 2019

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Purpose This study assessed the responsiveness to change over time and theorized associations of Patient‐Reported Outcomes Measurement Information System (PROMIS) pediatric measures in children and adolescents in treatment for cancer to determine measure readiness for use in cancer clinical trials. Methods We administered eight PROMIS (three symptom, two psychological, and three performance) pediatric short‐form measures and the Symptom Distress Scale (SDS) to 96 pediatric oncology patients at three time points during a course of chemotherapy. We assessed responsiveness using paired t tests and generalized estimating equation (GEE) models, calculated standardized response mean (SRM) values for PROMIS measures, and examined scores over three data points (T1–T3). Guided by the theory of unpleasant symptoms (TOUS), we examined associations among the PROMIS measures, the SDS, and other variables using GEE. Results The paired t tests showed statistically significant changes in two psychological measures and one performance measure from T1 to T2; three symptom, two psychological and two performance measures from T2 to T3; and three symptom and two psychological measures from T1 to T3. Findings from GEE models indicate PROMIS pediatric measures had statistically significant short‐term and long‐term changes, controlling for demographic and clinical variables. One performance measure did not achieve significant change at any time point. We found positive support for theorized relationships in the TOUS. Conclusions Most of the PROMIS pediatric measures demonstrated changes over time and had significant relationships as theorized, thus supporting concurrent and construct validity of these measures when administered to pediatric oncology patients during a course of chemotherapy. This evidence supports the measures’ readiness for use in clinical trials.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 58%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

Hinds

Wang

Cheng

et al. 2019

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our systematic search, we found 17 studies and one systematic review that assessed the psychometric properties of seven different measures for fatigue in CAYA cancer survivors [ 37 , 58 , 61 , 74 – 88 ]. Ten studies measured fatigue in CAYA cancer patients [ 74 , 76 – 80 , 82 , 83 , 86 , 87 ], five in CAYA cancer survivors [ 37 , 61 , 81 , 84 , 88 ], and three in a mixed patient and survivor population [ 58 , 75 , 85 ]. Five studies and the systematic review investigated the Fatigue Scales (Fatigue Scale-Child, Fatigue Scale-Adolescent, and proxy versions) [ 58 , 74 – 78 ], four studies the PROMIS Pediatric Fatigue Measures [ 82 – 85 ], three studies and the systematic review the PedsQL Multidimensional Fatigue Scale (Peds QL MFS) [ 74 , 79 – 81 ], and five studies other measures (Fatigue Thermometer [ 37 ], Multidimensional Fatigue Inventory [ 88 ] Turkish Scale for the Assessment of Fatigue in Pediatric Oncology Patients [ 86 , 87 ], and 12-item fatigue questionnaire [ 61 ]).…”

Section: Resultsmentioning

confidence: 99%

Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

et al. 2020

View full text Add to dashboard Cite

Purpose Cancer-related fatigue (CRF) negatively affects the lives of childhood, adolescent, and young adult (CAYA) cancer survivors. We aimed to provide an evidence-based clinical practice guideline (CPG) with internationally harmonized CRF surveillance recommendations for CAYA cancer survivors diagnosed < 30 years. Methods This CPG was developed by a multidisciplinary panel under the umbrella of the International Late Effects of Childhood Cancer Guideline Harmonization Group. After evaluating concordances and discordances of four existing CPGs, we performed systematic literature searches. We screened articles for eligibility, assessed quality, extracted, and summarized the data from included articles. We formulated recommendations based on the evidence and clinical judgment. Results Of 3647 articles identified, 70 articles from 14 countries were included. The prevalence of CRF in CAYA cancer survivors ranged from 10–85%. We recommend that healthcare providers are aware of the risk of CRF, implement regular screening with validated measures, and recommend effective interventions to fatigued survivors. Conclusions A considerable proportion of CAYA cancer survivors suffers from CRF even years after the end of treatment. Implications for Cancer Survivors We recommend that healthcare providers adopt regular screening to detect and treat CRF early and positively influence survivors’ health and quality of life.

show abstract

Recommended scoring approach for the pediatric patient‐reported outcomes version of the Common Terminology Criteria for Adverse Events

Hinds

Pinheiro

McFatrich

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background Collecting symptom, function, and adverse event (AE) data directly from children and adolescents undergoing cancer care is more comprehensive and accurate than relying solely on their caregivers or clinicians for their interpretations. We developed the pediatric patient‐reported outcomes version of the Common Terminology Criteria for Adverse Events (Ped‐PRO‐CTCAE) measurement system with input from children, parents, and clinicians. Here, we report how we determined the recommended Ped‐PRO‐CTCAE item scoring approach. Methods Data from 271 patients were analyzed using three scoring approaches: (a) at the AE attribute (frequency, severity, interference) using ordinal and dichotomous measures; (b) a weighted composite AE item score by AE attribute (0.5 ‐ frequency; 1.0 ‐ severity; 1.5 ‐ interference); and (c) overall number of AEs endorsed. Associations of each AE attribute, AE item score, and overall AE score with the Patient‐Reported Outcome Measurement Information System (PROMIS) Pediatric measures were examined. The ability of the overall Ped‐PRO‐CTCAE AE score to identify patients with PROMIS symptom T‐scores worse than reference population scores was assessed. Clinician preference for score information display was elicited through interviews with five pediatric oncology clinical trialists. Results The diverse scoring approaches yielded similar outcomes, including positive correlations of the Ped‐PRO‐CTCAE attributes, AE item score, and the overall AEs score with the PROMIS Pediatric measures. Clinicians preferred the most granular display of scoring information (actual score reported by the child and corresponding descriptive term). Conclusions Although three scoring approaches yielded similar results, we recommend the AE attribute level of one score per Ped‐PRO‐CTCAE AE attribute for its simplicity of use in care and research.

show abstract

Comparison of Legacy Fatigue Measures With the PROMIS Pediatric Fatigue Short Form

Abstract: Nurses have psychometrically strong options for measuring cancer-related fatigue in pediatric patients with cancer, but the PROMIS Pediatric Fatigue Short Form is applicable to more age groups.

Cited by 12 publications

References 27 publications

PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Recommended scoring approach for the pediatric patient‐reported outcomes version of the Common Terminology Criteria for Adverse Events

Contact Info

Product

Resources

About